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Introduction
Higher organisms have the remarkable capacity to 
produce and maintain adequate numbers of blood cells 
throughout their entire lifespan to meet the normal 
physiological requirements of blood cell turnover, as well 
as to respond to needs for increased blood cell demand as 
a consequence of injury or infection. At the center of 
lifelong blood cell production is the hematopoietic stem 
cell (HSC), with the capacity to give rise to all mature 
circulating blood cell types. Regulation of HSC function 
is a highly complex process involving not only intrinsic 
cues within the HSC themselves, but signaling from the 
surrounding microenvironment in which they reside. It 
was ﬁ   rst postulated by Schoﬁ   eld that deﬁ  ned  local 
microenvironments created specialized stem cell niches 
that regulated HSCs [1]. Bone marrow is the primary 
HSC niche in mammals and is composed of stromal cells 
and an extracellular matrix of collagens, ﬁ  bronectin, 
proteoglycans [2], and endosteal lining osteoblasts [3-6]. 
HSCs are thought to be tethered to osteoblasts, other 
stromal cells, and the extracellular matrix in this stem cell 
niche through a variety of adhesion molecule inter-
actions, many of which are probably redundant systems.
Disruption of one or more of these niche interactions 
can result in release of HSCs from the niche and their 
traﬃ     cking from the bone marrow to the peripheral 
circulation, a process termed peripheral blood stem cell 
mobilization. Mobilization can be achieved through 
adminis  tration of chemotherapy [7-9], hematopoietic 
growth factors, chemokines and small-molecule chemo-
kine receptor inhibitors or antibodies against HSC niche 
interactions [10-12].
Th  e process of mobilization has been exploited for 
collection of hematopoietic stem and progenitor cells 
(HSPCs) and is widely used for hematopoietic trans-
plantation in both the autologous and allogeneic settings. 
Mobilized peripheral blood hematopoietic stem cell 
grafts are associated with more rapid engraftment, 
reduc  tion in infectious complications and, in patients 
with advanced malignancies, lower regimen-related mor-
tality [13-15] compared with bone marrow grafts. In 
many trans  plantation centers, mobilized HSC grafts are 
now the preferred hematopoietic stem cell source used 
for human leukocyte antigen-identical sibling transplants 
as well as for matched related and unrelated donor 
transplants [16,17]. Granulo  cyte colony-stimulating factor 
(G-CSF), granulocyte–macrophage colony-stimulating 
factor and – more recently, for patients who fail to 
mobilize with a G-CSF or granulocyte–macro  phage 
colony-stimulating factor – plerixafor (AMD3100) are 
the only US Food and Drug Adminis  tration-approved 
agents for mobilizing HSCs. Despite the clinical 
prevalence of peripheral blood stem and pro  genitor cell 
mobilization, the mechanisms orchestrating the release 
of these cells from the hematopoietic niche are still not 
completely understood. In the following sections, we 
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can enhance their release from the niche and entry 
into the peripheral circulation. This process, termed 
mobilization, has become the primary means to 
acquire a stem cell graft for hematopoietic transplant 
at most transplant centers. Currently, the preferred 
method of HSC mobilization for subsequent 
transplantation is treatment of the donor with 
granulocyte colony-stimulating factor. The mobilizing 
eff  ect of granulocyte colony-stimulating factor is not 
completely understood, but recent studies suggest 
that its capacity to mobilize HSCs, at least in part, is 
a consequence of alterations to the hematopoietic 
niche. The present article reviews some of the key 
mechanisms mediating HSC mobilization, highlighting 
recent advances and controversies in the fi  eld.
© 2010 BioMed Central Ltd
Mobilization of hematopoietic stem cells from the 
bone marrow niche to the blood compartment
Jonathan Hoggatt and Louis M Pelus*
REVIEW
*Correspondence: lpelus@iupui.edu
Department of Microbiology & Immunology, Indiana University School of 
Medicine, 950 West Walnut Street, R2-302, Indianapolis, IN 46202, USA
Hoggatt and Pelus Stem Cell Research & Therapy 2011, 2:13 
http://stemcellres.com/content/2/2/13
© 2011 BioMed Central Ltdhighlight some of the key mechanistic ﬁ   nd ings  con cern-
ing HSPC mobilization, with an emphasis on the eﬀ  ects 
of mobilizing agents on bone marrow niche interactions.
CXCR4/SDF-1α: the paradigm of mobilization
Th   e most explored HSC niche interaction is between the 
CXC4 chemokine receptor (CXCR4) and its ligand, 
stromal cell-derived factor 1α (SDF-1α). SDF-1α is pro-
duced by osteoblasts [18], a specialized set of reticular 
cells found in endosteal and vascular niches [19], endo-
thelial cells and bone itself [20,21], and high levels of 
SDF-1α were observed recently in nestin-positive mesen-
chymal stem cells [22]. HSPCs express CXCR4 and are 
chemoattracted to and retained within the bone marrow 
by SDF-1α [23-25]. Genetic knockout of either CXCR4 
[26] or SDF-1α [27] in mice is embryonically lethal, with 
a failure of HSPCs to traﬃ   c to the bone marrow niche 
during development. In addition, conditional CXCR4 
knock  out in mice results in a substantial egress of 
hemato  poietic cells from the bone marrow [28] and 
impaired ability of CXCR4 knockout HSPCs to be re-
tained within the bone marrow after transplantation [29].
Many agents reported to mobilize HSCs have been 
shown to disrupt the CXCR4/SDF-1α axis. Most notably, 
the CXCR4 antagonist AMD3100 (Plerixafor; MozobilTM, 
Genzyme  Corporation, Cambridge, MA, USA) mobilizes 
HSPCs [30-35]; and similarly, the CXCR4 antagonists 
T140 [36] and T134 [37] are both capable of mobilization. 
Partially agonizing CXCR4 with SDF-1α mimetics 
including (met)-SDF-1β [38], CTCE-0214 [39], and 
CTCE-0021 [35] also mobilizes HSCs through CXCR4 
receptor desensitization and/or down  regulation of 
surface CXCR4 expression. Intriguingly, these agents that 
directly disrupt the CXCR4/SDF-1α axis lead to rapid 
mobilization of HSPCs – that is, hours after treatment – 
in contrast to other mobilization agents like G-CSF, 
which take several days to maximally mobilize HSPCs.
Despite the abundance of evidence supporting a key 
role for the CXCR4/SDF-1α axis in HSPC retention/
traﬃ   cking/mobilization, it is still not clear which popu-
lation of cells within the bone marrow niche is the pre-
dominate source of SDF-1α. Some studies have demon-
strated that SDF-1α production by osteoblasts is reduced 
after G-CSF treatment [21,40,41], and seminal work by 
Katayama and colleagues suggests that this reduction in 
osteoblast SDF-1α is at least partly mediated by the 
sympathetic nervous system [21]. Notwithstanding the 
fact that decreased levels of SDF-1α production by osteo-
blasts are routinely seen following G-CSF administration, 
however, other studies have questioned the relative 
importance of osteoblast-derived SDF-1α in HSC main-
te  nance and mobilization [19,22,42]. A recent study by 
Christopher and colleagues indicated that reduction in 
osteoblast production of SDF-1α is a common mechanism 
of cytokine-induced HSC mobilization and showed a 
speciﬁ   c reduction in SDF-1α production in Col2.3-
expressing osteoblasts with no reduction in Col2.3-
negative stromal cells [43]. Mendez-Ferrer and colleagues, 
however, showed, using a similar approach, a substantial 
decrease in SDF-1α in a novel population of nestin-
expressing mesenchymal stem cells [22], relative to a 
similar population of stromal cells described by 
Christopher and colleagues [43], although a direct com-
parison with deﬁ  ned osteoblasts was not made. Future 
studies are clearly required in order to deﬁ  ne the speciﬁ  c 
niche cells responsible for SDF-1α production and HSC 
retention, and may identify speciﬁ   c targets for future 
HSC therapies.
There is more to an osteoblast than SDF-1α
Osteoblasts are important HSC regulators [3-6], and 
express numerous signaling molecules in addition to 
SDF-1α that regulate HSC function and retention in the 
bone marrow niche. Osteoblasts express vascular cell 
adhesion molecule 1 (VCAM-1), and targeting the inter-
action between very late antigen 4 (VLA-4) and VCAM-1 
with either antibodies against VLA-4 [44,45], antibodies 
against VCAM-1 [46,47], or a small molecule inhibitor of 
VLA-4 (BIO5192) [48] results in HPSC mobilization. In 
addition, the Eph–ephrin A3 signaling axis increases 
adhesion to ﬁ  bronectin and VCAM-1, and disruption of 
this signaling axis in vivo with a soluble EphA3-Fc fusion 
protein mobilizes HSPCs [49].
Osteoblasts also express signiﬁ  cant amounts of osteo-
pontin, and HSPCs adhere to osteopontin via β1 integrins, 
such as VLA-4 [50]. Osteopontin is a negative regulator 
of HSC pool size within the bone marrow niche [50,51], 
and knockout of osteopontin in mice results in endo  ge-
nous HSPC mobilization and increases the mobilization 
response to G-CSF [52]. Future therapies that target 
osteo  pontin may not only increase the HSC pool size 
available for hematopoietic mobilization, but may also 
act to untether the expanded HSCs from the bone 
marrow niche, resulting in signiﬁ  cantly enhanced HSC 
mobilization.
Mobilizing regimens of G-CSF are associated with 
suppression of niche osteoblasts [21,41,53], with increased 
osteoblast apoptosis [41] and osteoblast ﬂ  attening [21], 
resulting in signiﬁ   cant decreases in endosteal niche 
expres  sion of many of the above-mentioned retention 
molecules. Th   is suppression has been reported to be the 
result of altered sympathetic nervous system signaling to 
osteoblasts [21]. A recent report by Winkler and colleagues 
demonstrated that G-CSF treatment results in the 
reduction of endosteal-lining osteomacs, which results in 
suppression of osteoblasts [53]. Th   is osteomac population 
of cells is F4/80+ Ly-6G+ CD11b+ and provides a yet to be 
deter  mined positive supporting role for osteoblasts. 
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mice or by treatment of mice with clodronate-loaded 
liposomes, signiﬁ   cant mobilization of HSPCs was 
observed. Th  ese  ﬁ  ndings support a mechanistic role for 
osteoblasts in mediating G-CSF-induced mobilization, 
independent of the sympathetic nervous system, and 
highlight that multiple mechanisms may be responsible 
for the mobilizing eﬀ  ects of G-CSF.
What about osteoclasts?
Osteoblasts and osteoclasts regulate/coordinate bone 
formation and bone resorption, respectively, within the 
bone marrow niche. A report from Kollet and colleagues 
suggested that osteoclasts can mediate HSPC mobiliza-
tion [54], and proposed a model where the balance 
between osteoblasts and osteoclasts is required for 
homeo  static maintenance of the stem cell niche and 
HSPC pool size. In their model, increased osteoblasts – 
for example, after parathyroid hormone administration 
[3] – increase the stem cell pool size and adherence in the 
niche, whereas increased osteoclasts degrade the niche – 
facilitating release and egress of HSPCs.
A role for osteoclasts in mobilization was shown by 
treating mice with RANK ligand, which increased osteo-
clast activity that correlated with a moderate increase in 
hematopoietic progenitor cell (HPC) mobilization [54]. 
Similarly, bleeding mice or treating them with lipopoly-
saccharide, two models of physiological stress, resulted in 
an increase in the number of bone marrow niche osteo-
clasts as well as HPC mobilization. Inhibition of osteo-
clasts, either by treat  ment with calcitonin or using a 
genetic knockout model of PTPε in female mice, resulted 
in a reduced HPC mobiliza  tion response to G-CSF com-
pared with controls, further suggesting that osteoclasts 
were involved in G-CSF-mediated mobilization. Th  e 
authors proposed that osteoclast-derived proteolytic 
enzymes, such as cathep  sin K, degraded important niche 
interaction components including SDF-1α and osteo  pon-
tin, thereby facilitating mobilization [54]. A more recent 
study by the same laboratory demonstrated reduced 
osteoclast maturation and activity in CD45 knockout 
mice, which correlated with reduced mobilization to 
RANK ligand and G-CSF [55], providing an additional 
link between osteoclast activity and HSPC mobilization.
In contrast to studies showing that increased osteo-
clasts enhance HPC mobilization, an earlier report by 
Takamatsu and colleagues demonstrated that while 
G-CSF treatment increases osteoclast number and bone 
resorption in both BALB/c mice and humans, the 
increase in osteoclasts did not occur until 10 to 15 days 
or 6 to 8 days, respectively, after treatment with G-CSF 
[56] – a ﬁ  nding that has also been observed by other 
groups using similar systems [40,57]. Since HSPC 
mobiliza  tion by G-CSF is typically evaluated after 4 to 
5 days, the importance of osteoclasts to HSPC mobiliza-
tion in response to G-CSF treatment remains unclear. 
Furthermore, treatment of mice with bisphosphonates, 
which inhibit osteoclast activity and/or number, prior to 
G-CSF administration does not result in an impaired 
HSPC mobilization response [53,56]; in fact, in one case, 
bisphosphonate treatment increased mobilization by 
G-CSF [53]. Th   ese studies suggest that while osteoclasts 
elicit mechanisms that can induce hematopoietic stem 
and progenitor mobilization, their role in clinical HSC 
mobilization with G-CSF is not suﬃ   ciently deﬁ  ned and 
may not be a primary mechanism of mobilization.
Th   e endosteal surface of bone, particularly at the site of 
resorbing osteoclasts, is a signiﬁ  cant source of soluble 
extracellular calcium within the bone marrow niche. 
Studies by Adams and colleagues demonstrated that 
HSCs express calcium-sensing receptors and are chemo-
attracted to soluble Ca2+ [58]. When the gene for the 
calcium-sensing receptor was knocked out, mice had 
reduced HSC content within the bone marrow niche and 
increased HSCs in peripheral blood. Moreover, calcium-
sensing receptor-knockout HSCs failed to engraft in 
hemato  poietic transplantation experiments. Th  ese  results 
suggest that Ca2+ at the endosteal surface is an important 
retention signal within the hematopoietic niche and that 
pharmacologic antagonism of the HSC calcium-sensing 
receptor may represent a possible strategy for HSPC 
mobilization.
Oxygen regulation of hematopoietic stem cell 
mobilization
Th   e bone marrow hematopoietic niche has been shown 
to be hypoxic [59,60]. HSCs that reside in hypoxic niches 
have also been shown to have greater hematopoietic-
repopulating ability than those that do not [61]. A known 
physiolo  gical response to hypoxia is stabilization of the 
trans  crip  tion factor hypoxia inducible factor 1α (HIF-1α). 
HIF-1α has been shown to upregulate erythropoietin 
production [62], numerous cell proliferation and survival 
genes [63-65], the angiogenic vascular endothelial growth 
factor [66], and other genes. It has also been suggested 
that the hypoxic bone marrow niche maintains HIF-1α 
activity, thereby maintaining stem cells [67] – a 
hypothesis supported by the fact that hypoxic conditions 
expand human HSCs [68] and HPC populations [69-71] 
in vitro. In response to G-CSF, both the hypoxic environ-
ment and HIF-1α expand within the bone marrow 
compartment [72] and increase production of vascular 
endothelial growth factor A; however, bone marrow 
vascular density and permeability are not increased [61]. 
HIF-1α also increases production of SDF-1α [73] and 
CXCR4 receptor expression [74], suggesting that hypoxia 
may be a physiological regulator of this important 
signaling axis within the hematopoietic niche.
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poietic cell damage caused by overproduction of reactive 
oxygen species [75], suggesting that the hypoxic niche 
helps maintain the long lifespan of HSCs. However, some 
small degree of reactive oxygen species signaling may be 
necessary for HSC mobilization. A recent report demon-
strated that enhanced c-Met activity promotes HSPC 
mobilization by activating mTOR and increasing reactive 
oxygen species production in HSPCs [76], while inhibi-
tion of mTOR with rapamycin reduced HSC mobilization 
[76,77]. Genetic knockout of the gene for thioredoxin-
interacting protein also results in increased HSPC 
mobili  za  tion under stress conditions [78], suggesting a 
role for oxygen tension and reactive oxygen species in 
regulation of hematopoietic stem and progenitor mobili  za-
tion. Th  ese  ﬁ  ndings clearly warrant additional exploration.
Control of the bone marrow niche by the nervous 
system
It has been known for some time that there is dynamic 
interaction between the bone marrow niche and the 
nervous system. Studies by Katayama and colleagues 
demonstrated that HSPC mobilization by G-CSF requires 
peripheral β2-adrenergic signals [21], showing that G-
CSF mobilization was reduced in chemically sym  pa-
thecto  mized mice treated with 6-hydroxydopamine, in 
mice treated with the β-blocker propanolol, or in mice 
genetically deﬁ   cient in the gene for dopamine β-
hydroxylase (Dbh), an enzyme that converts dopamine 
into norepinephrine. Th  ey also showed that treatment 
with the β2-adrenergic agonist clenbuterol reversed the 
phenotype of Dbh knockout mice [21]. Intriguingly, 
G-CSF attenuated osteoblast function via the sympathetic 
nervous system resulting in osteoblasts having a marked 
ﬂ  attened appearance. Th  e  eﬀ  ects of nervous system signal-
ing can also be mediated directly on HSCs, as human 
CD34+ hemato  poietic cells express β2-adrenergic and 
dopamine receptors that are upregulated after G-CSF 
treatment [79]. Neurotransmitters serve as direct chemo-
attractants to HSPCs, and treatment with nor  epinephrine 
results in HSC mobilization [79]. Norepi  neph  rine treat-
ment of mice has also been shown to increase CXCR4 
receptor expression [80], perhaps suggesting that adre-
ner  gic signal  ing could directly aﬀ  ect  CXCR4/SDF-1α 
signaling in HSPCs. Additional studies directly assessing 
eﬀ  ects of neurotransmitter signaling in HSPCs will help 
to further deﬁ   ne the role of the nervous system in 
hematopoietic regulation.
Not only does the sympathetic nervous system aﬀ  ect 
HSC mobilization during stress situations, but it also 
regu  lates HSC traﬃ   cking via a circadian rhythm [81,82]. 
β3-Adrenergic stimulations demonstrate regular oscilla-
tions controlling norepinephrine release, CXCR4 expres-
sion, and SDF-1α production, leading to rhythmic release 
of HSPCs from the bone marrow niche. Intriguingly, 
while optimal mobilization occurs in the morning in 
mice (Zeitgeber time 5), HSC mobilization circadian 
control is inverted in humans, with peak mobilization 
occurring later in the evening [81]. Mobilization by both 
G-CSF and AMD3100 is aﬀ  ected by circadian control of 
the CXCR4/SDF-1α axis. Recently, it was demonstrated 
that β2-adrenergic signaling upregu  lates the vitamin D 
receptor on osteoblasts; that expres  sion of this receptor 
is necessary for the G-CSF-induced suppression of osteo-
blast function; and that vitamin D receptor knockout 
mice have reduced HSC mobilization [83]. Intriguingly, 
vitamin D recep  tor is an important regulator of 
extracellular calcium and HSPC localization [84] and the 
receptor is also regulated by circadian rhythms [85], 
possibly suggesting additional inter  con  nected 
mobilization mechanisms. Further assess  ment of the role 
of nervous system signaling and vitamin D recep  tor 
signaling on other niche cells, particularly mesen  chymal 
stem cells, should be performed.
Conclusion
Th   ere has been signiﬁ  cant progress in understanding the 
mechanisms of action of G-CSF and other stimuli that 
increase HSPC traﬃ   cking/mobilization. As described in 
the present review, however, there is currently an abun-
dance of proposed mechanisms that may be responsible 
for mobilization. Th   is raises the question of whether the 
proposed mechanisms, be they HSPC intrinsic or 
manifested through the bone marrow niche, truly 
represent alternate and independent means to mobilize 
or enhance egress of HSPCs from bone marrow to the 
circulation, or whether we have not yet found the 
unifying mechanism.
Intriguingly, many of the proposed mechanisms of 
mobilization converge on the CXCR4/SDF-1α pathway 
(Figure 1). Alterations of the osteoblast/osteoclast 
balance result in a reduction of SDF-1α production and/
or degradation of SDF-1α by proteases. Signaling from 
the sympathetic nervous system, stimulated by G-CSF, 
can alter the osteoblast/osteoclast balance leading to 
reduced CXCR4/SDF-1α signaling and HSPC mobiliza-
tion. Circadian rhythms act to reduce niche SDF-1α 
production and HSPC CXCR4 expression in an oscillat-
ing manner, suggesting that clinical mobilization should 
be performed at the trough of SDF-1α and CXCR4 
expres  sion (early night for humans) and perhaps suggest-
ing that clinical transplantation should be performed at 
the peak of expression (early morning in humans). Th  e 
hypoxic nature of the hematopoietic bone marrow niche 
may itself regulate the CXCR4/SDF-1α signaling axis, 
perhaps further identifying this axis as a unifying 
mobilization mechanism. Th  e importance of CXCR4 
signaling in HSPC retention and mobilization is certainly 
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antagonize, or compete with SDF-1α and partially ago  nize, 
the CXCR4 receptor and result in HSPC mobili  zation. 
Even a rapid mobilizing agent such as GROβ (CXCR2 
agonist) may function by increasing proteolytic cleavage of 
SDF-1α [86,87], or altering a homeostatic balance between 
the CXCR4 and CXCR2 signaling path  ways [88].
While perhaps connecting many of the proposed 
mechanistic pathways for HSPC mobilization, however, 
the CXCR4/SDF-1α pathway does not appear to be an 
exclusive target for HSPC mobilization. Continued 
investigation of the molecular mechanism(s) for action of 
G-CSF and other HSPC mobilizers is warranted and may 
deﬁ  ne new molecular targets that can be used to enhance 
the magnitude and/or ease of HSPC collection for 
hematopoietic transplant.
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Figure 1. Hematopoietic stem and progenitor mobilization converges on the CXCR4/SDF-1α signaling axis within the hematopoietic 
niche. Many of the proposed mechanisms for hematopoietic stem and progenitor mobilization function by altering the marrow 
microenvironmental CXC4 chemokine receptor (CXCR4)/stromal cell-derived factor 1α (SDF-1α) signaling axis. Shown are representative mobilization 
mechanisms and their relationship to the CXCR4/SDF-1α axis. Question marks denote hypothetical linkage to the CXCR4/SDF-1α axis. G-CSF, 
granulocyte colony-stimulating factor; HSC, hematopoietic stem cell; HSPC, hematopoietic stem and progenitor cell; ROS, reactive oxygen species.
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